RXRX · Recursion Pharmaceuticals, Inc.
$2.96
-0.05 (-1.66%)
At close · Jul 24
Market Cap
$1.57B
Shares
529.91M
Recursion Pharmaceuticals, Inc. Earnings Call Transcripts
Every quarterly earnings call for Recursion Pharmaceuticals, Inc. (RXRX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲439.9%
$13.68M
−$57.49M
'22 Q4
23-02-27
▲127.5%
$12.13M
−$65.33M
'23 Q1
23-05-08
▼20.4%
$10.89M
−$93.00M
'23 Q4
24-02-27
▲13.7%
$13.79M
−$91.37M
'24 Q1
24-05-09
▲30.9%
$14.42M
−$97.54M
'24 Q2
24-08-08
▼58.3%
$4.55M
−$178.91M
'24 Q4
25-02-28
▲6.9%
$14.74M
−$202.49M
'25 Q1
25-05-05
▲33.3%
$19.22M
−$171.90M
'25 Q2
25-08-05
▼80.2%
$5.17M
−$162.25M
'25 Q3
25-11-05
▲681.7%
$35.54M
−$108.12M
'25 Q4
26-02-25
LATEST
▼56.1%
$6.47M
−$117.50M
'26 Q1
26-05-06
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Recursion Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone
AI-native product engine and platform
Wholly owned clinical pipeline
Clinical proof points and catalysts
Revenue
$6.47M
▼ 56.1% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Recursion Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone
Upcoming catalysts and FDA engagement
Sanofi partnership and milestones
Clinical pipeline and FAP proof of concept
Revenue
$35.54M*
▲ 681.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Recursion Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone
Roche/Genentech partnership & milestones
CEO leadership transition
Partnership strategy (incl. Sanofi, new deals)
Revenue
$5.17M
▼ 80.2% YoY Diluted EPS
$-0.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Recursion Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone
Internal pipeline programs
Recursion OS platform
Boltz-2 partnership and open source
Revenue
$19.22M
▲ 33.3% YoY Diluted EPS
$-0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Recursion Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Positive tone
Discontinued Programs
Pharma Partnerships
Rare Disease / FAP Program
Revenue
$14.74M
▲ 6.9% YoY Diluted EPS
$-0.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-28
Recursion Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone
TechBio platform and AI/ML capabilities
Pharma partnerships and milestones
NIH funding concerns and ecosystem risk
Revenue
$4.55M*
▼ 58.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2024-08-08
Recursion Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone
Pharma partnerships
Pipeline and clinical readouts
Exscientia combination
Revenue
$14.42M
▲ 30.9% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Recursion Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone
Industry outlook and competition
Strategic partnerships and collaborations
Platform and data layers
Revenue
$13.79M
▲ 13.7% YoY Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Recursion Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone
Partnerships
TechBio platform and Recursion OS
Pipeline and clinical milestones
Revenue
$10.89M*
▼ 20.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q1
2023-05-08
Recursion Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$12.13M
▲ 127.5% YoY Diluted EPS
$-0.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Recursion Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Revenue
$13.68M*
▲ 439.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–12 of 12 earnings calls
Key facts
CIK
1601830
CUSIP
75629V104
13F (30d)
60 filings
60 filers
Visit website
Investor relations